How Retatrutide Works.

Retatrutide is an investigational (not yet broadly approved) once-weekly injectable medicine being studied for obesity and related metabolic conditions. It’s often called a “triple agonist” because it activates three hormone receptors at once:

• GLP-1 receptor

• GIP receptor

• Glucagon receptor

How it works (in plain English)

Think of it as combining three metabolic signals:

1. GLP-1 effect → helps reduce appetite, slows stomach emptying, improves blood sugar control.

2. GIP effect → works with GLP-1 to improve insulin response and metabolic regulation.

3. Glucagon effect → may increase energy expenditure and fat mobilization (this is the “extra lever” vs GLP-1-only drugs).

​

What are these three weight management agonists?

​

1) GLP-1 receptor action

(GLP-1 = glucagon-like peptide-1)

​

What it mainly does

• Reduces appetite and increases satiety signals (you feel full sooner)

• Slows stomach emptying, so food leaves the stomach more gradually

• Improves glucose control by boosting insulin secretion when glucose is elevated

These are core mechanisms shared with GLP-1-based medicines and are a big reason people eat less overall.

What you might notice clinically

• Smaller meal portions

• Less “food noise”

• Early GI effects (nausea/fullness), especially during dose increases

2) GIP receptor action

(GIP = glucose-dependent insulinotropic polypeptide)

​

What it mainly does

• Works with GLP-1 on post-meal insulin signaling and glycemic control

• Appears to help metabolic efficiency and may improve tolerability/efficacy when paired with GLP-1 in dual/triple agonist designs

In retatrutide, this is part of the “stacked” incretin effect—more than just GLP-1 alone.

What you might notice clinically

• Better post-meal glucose handling

• Additional support for weight reduction when combined with GLP-1 and glucagon pathways (synergy shown in trials)

3) Glucagon receptor action

(GCGR = glucagon receptor)

​

What it mainly does

• May increase energy expenditure (calories burned), which is the key differentiator vs GLP-1-only therapy

• May also contribute to fat mobilization and liver/metabolic effects

This third lever is why retatrutide is often discussed as potentially stronger for weight loss than single- or dual-pathway agents—but it also needs careful dose titration and monitoring.

What you might notice clinically

• Potentially greater total weight-loss effect in combination with appetite reduction

• Still with GI side effects as the most common tolerability issue pattern in trials

Why combining all 3 can be powerful

A simple way to picture it:

• GLP-1: “Eat less”

• GIP: “Handle nutrients/glucose better”

• Glucagon: “Burn more”

• ​

So retatrutide is designed to affect both sides of the energy equation (intake + expenditure), while improving glycemic control. Early- and mid-stage data support that this combination can produce large weight-loss effects.